Gastric Ulcer Treatment Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The gastric ulcer treatment market was valued at USD 2.12 Billion in 2024, driven by the rising incidence of gastric ulcers and related complications across the 8 major markets. It is expected to grow at a CAGR of 2.80% during the forecast period of 2025-2034, with the values likely to reach USD 2.79 Billion by 2034.
Gastric Ulcer Treatment Market Overview
Gastric ulcers, also known as stomach ulcers, are open sores that develop on the inner lining of the stomach. They occur when the stomach's protective mucus layer is damaged, allowing stomach acid to erode the underlying tissue. This can cause pain, bleeding, and other gastrointestinal symptoms. Gastric ulcers are often caused by infections with Helicobacter pylori bacteria or the prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs). Treatment typically involves the use of medications such as proton pump inhibitors (PPIs) and H2 receptor antagonists to reduce stomach acid, antibiotics to eradicate Helicobacter pylori infection, and lifestyle modifications to address contributing factors like diet and NSAID use. In some cases, treatment may also include antacids, protective agents, and surgical procedures for severe or complicated ulcers.
The gastric ulcer treatment market is expanding due to growing healthcare spending in developing and developed countries enhancing access to advanced ulcer treatments. Expanding healthcare infrastructure in emerging markets increases the availability and accessibility of gastric ulcer treatments. Also, unhealthy lifestyle habits, such as poor diet, smoking, and excessive alcohol consumption, contribute to the increasing prevalence of gastric ulcers, driving the need for treatments.
Gastric Ulcer Treatment Market Growth Drivers
Advancements in Medical Research Augmenting the Market Growth
Advancements in medical research are crucial for the development of new and more effective treatments for gastric ulcers. These innovations lead to better therapeutic options, improving patient outcomes and driving market growth. For Instance, in January 2023, Takeda announced favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). The trial also assessed the pharmacokinetics (PK) characteristics of TAK-755, along with long-term data on TAK-755 prophylaxis from a Phase 3b continuation study. This new medication, developed through advanced research and innovative drug design, promises to provide enhanced relief for patients with gastric ulcers, highlighting the impact of ongoing medical research on market growth.
Strategic Collaborations and Partnerships to Meet Rising Gastric Ulcer Treatment Market Demand
Strategic collaborations and partnerships between pharmaceutical companies are accelerating the development and commercialization of new gastric ulcer treatments. These alliances combine resources and expertise, leading to innovative solutions and faster market entry. For Instance, AstraZeneca plc and Daiichi Sankyo Company Limited in collaboration announced the launch of Nexium® Granules for Suspension, Sachet, in 10 mg and 20 mg doses (generic name: esomeprazole magnesium hydrate). It is a proton pump inhibitor indicated for gastric ulcers, duodenal ulcers, anastomotic ulcers, reflux esophagitis, and nonerosive reflux disease. This partnership aimed to leverage AstraZeneca’s expertise in gastrointestinal therapies and Daiichi Sankyo’s advanced drug development technologies. The collaboration is expected to expedite the availability of this new treatment, demonstrating how strategic partnerships drive innovation and growth in the gastric ulcer treatment market.
Gastric Ulcer Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
The widespread dependence on NSAIDs as a treatment for various indications is boosting the demand for gastric ulcer treatment, as this category of drugs is often associated with ulcer-related complications.
Rising Helicobacter pylori Infection
The high prevalence of Helicobacter pylori infection is one of the major causes of gastric ulcers, driving the demand for appropriate therapies.
Technological Advancements
Innovations in drug delivery systems and treatment methodologies enhance the efficacy and patient compliance of gastric ulcer treatments.
Regulatory Approvals
Favorable regulatory policies and faster approval processes for new gastric ulcer treatments are some of the major market trends, supporting market growth significantly.
Gastric Ulcer Treatment Market Segmentation
“Gastric Ulcer Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth
By Drug Class, the market is segmented into antacids, anti-histamines, antibiotics, H2 receptor antagonists, and proton pump inhibitors (PPIs). Increasing disposable income in emerging markets allows for greater spending on healthcare and advanced treatments for gastric ulcers. Collaborations between pharmaceutical companies and research institutions are accelerating the development of new treatments and expanding market reach. Growing preference for non-invasive and minimally invasive treatments boosts the demand for advanced therapeutic options for gastric ulcers.
Gastric Ulcer Treatment Market Analysis by Region
Based on the region, the market report covers the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. The United States is dominating the market share due to the high economic burden of managing chronic diseases, motivating the adoption of effective treatments like gastric ulcer treatment to improve patient outcomes and reduce healthcare costs.
EU-4 also holds a high gastric ulcer treatment market value driven by the improvements in healthcare infrastructure in emerging markets increasing the availability and adoption of gastric ulcer treatment. Additionally, Japan is expected to witness substantial market growth fueled by the growing patient pool and the increasing recognition of gastric ulcer treatment benefits. An aging population is more susceptible to chronic diseases, thereby increasing the demand for gastric ulcer treatment.
Leading Players in the Gastric Ulcer Treatment Market
The key features of the market report include patent analysis, clinical trials analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca PLC
It is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and respiratory therapy areas. In the field of gastric ulcer treatment, AstraZeneca is known for developing effective medications such as proton pump inhibitors (e.g., Nexium) that reduce stomach acid and promote ulcer healing. The company leverages its extensive research and development capabilities to continuously innovate and improve treatment options for gastric ulcers and other gastrointestinal conditions.
Takeda Pharmaceutical Company Limited
A global, research and development-driven biopharmaceutical company headquartered in Japan, Takeda focuses on developing innovative medicines in areas such as oncology, gastroenterology, neuroscience, and rare diseases. In the realm of gastric ulcer treatment, it offers effective therapies like proton pump inhibitors (e.g., Lansoprazole) that help reduce stomach acid and promote healing. The company is committed to improving patient outcomes through advanced research and a strong pipeline of therapeutic solutions.
Other key players in the market include Boehringer Ingelheim International GmbH, Nuvo Pharmaceuticals Inc. (Aralez Pharmaceuticals), Daiichi Sankyo Company, Limited, Novartis AG, and Pfizer Inc., among others.
Key Questions Answered in the Gastric Ulcer Treatment Market Report
Gastric Ulcer Treatment Market Overview
Gastric ulcers, also known as stomach ulcers, are open sores that develop on the inner lining of the stomach. They occur when the stomach's protective mucus layer is damaged, allowing stomach acid to erode the underlying tissue. This can cause pain, bleeding, and other gastrointestinal symptoms. Gastric ulcers are often caused by infections with Helicobacter pylori bacteria or the prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs). Treatment typically involves the use of medications such as proton pump inhibitors (PPIs) and H2 receptor antagonists to reduce stomach acid, antibiotics to eradicate Helicobacter pylori infection, and lifestyle modifications to address contributing factors like diet and NSAID use. In some cases, treatment may also include antacids, protective agents, and surgical procedures for severe or complicated ulcers.
The gastric ulcer treatment market is expanding due to growing healthcare spending in developing and developed countries enhancing access to advanced ulcer treatments. Expanding healthcare infrastructure in emerging markets increases the availability and accessibility of gastric ulcer treatments. Also, unhealthy lifestyle habits, such as poor diet, smoking, and excessive alcohol consumption, contribute to the increasing prevalence of gastric ulcers, driving the need for treatments.
Gastric Ulcer Treatment Market Growth Drivers
Advancements in Medical Research Augmenting the Market Growth
Advancements in medical research are crucial for the development of new and more effective treatments for gastric ulcers. These innovations lead to better therapeutic options, improving patient outcomes and driving market growth. For Instance, in January 2023, Takeda announced favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). The trial also assessed the pharmacokinetics (PK) characteristics of TAK-755, along with long-term data on TAK-755 prophylaxis from a Phase 3b continuation study. This new medication, developed through advanced research and innovative drug design, promises to provide enhanced relief for patients with gastric ulcers, highlighting the impact of ongoing medical research on market growth.
Strategic Collaborations and Partnerships to Meet Rising Gastric Ulcer Treatment Market Demand
Strategic collaborations and partnerships between pharmaceutical companies are accelerating the development and commercialization of new gastric ulcer treatments. These alliances combine resources and expertise, leading to innovative solutions and faster market entry. For Instance, AstraZeneca plc and Daiichi Sankyo Company Limited in collaboration announced the launch of Nexium® Granules for Suspension, Sachet, in 10 mg and 20 mg doses (generic name: esomeprazole magnesium hydrate). It is a proton pump inhibitor indicated for gastric ulcers, duodenal ulcers, anastomotic ulcers, reflux esophagitis, and nonerosive reflux disease. This partnership aimed to leverage AstraZeneca’s expertise in gastrointestinal therapies and Daiichi Sankyo’s advanced drug development technologies. The collaboration is expected to expedite the availability of this new treatment, demonstrating how strategic partnerships drive innovation and growth in the gastric ulcer treatment market.
Gastric Ulcer Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
The widespread dependence on NSAIDs as a treatment for various indications is boosting the demand for gastric ulcer treatment, as this category of drugs is often associated with ulcer-related complications.
Rising Helicobacter pylori Infection
The high prevalence of Helicobacter pylori infection is one of the major causes of gastric ulcers, driving the demand for appropriate therapies.
Technological Advancements
Innovations in drug delivery systems and treatment methodologies enhance the efficacy and patient compliance of gastric ulcer treatments.
Regulatory Approvals
Favorable regulatory policies and faster approval processes for new gastric ulcer treatments are some of the major market trends, supporting market growth significantly.
Gastric Ulcer Treatment Market Segmentation
“Gastric Ulcer Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Antacids
- Anti-Histamines
- Antibiotics
- H2 Receptor Antagonist
- Proton Pump Inhibitor (PPIs)
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Oral
- Parenteral
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth
By Drug Class, the market is segmented into antacids, anti-histamines, antibiotics, H2 receptor antagonists, and proton pump inhibitors (PPIs). Increasing disposable income in emerging markets allows for greater spending on healthcare and advanced treatments for gastric ulcers. Collaborations between pharmaceutical companies and research institutions are accelerating the development of new treatments and expanding market reach. Growing preference for non-invasive and minimally invasive treatments boosts the demand for advanced therapeutic options for gastric ulcers.
Gastric Ulcer Treatment Market Analysis by Region
Based on the region, the market report covers the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. The United States is dominating the market share due to the high economic burden of managing chronic diseases, motivating the adoption of effective treatments like gastric ulcer treatment to improve patient outcomes and reduce healthcare costs.
EU-4 also holds a high gastric ulcer treatment market value driven by the improvements in healthcare infrastructure in emerging markets increasing the availability and adoption of gastric ulcer treatment. Additionally, Japan is expected to witness substantial market growth fueled by the growing patient pool and the increasing recognition of gastric ulcer treatment benefits. An aging population is more susceptible to chronic diseases, thereby increasing the demand for gastric ulcer treatment.
Leading Players in the Gastric Ulcer Treatment Market
The key features of the market report include patent analysis, clinical trials analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AstraZeneca PLC
It is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and respiratory therapy areas. In the field of gastric ulcer treatment, AstraZeneca is known for developing effective medications such as proton pump inhibitors (e.g., Nexium) that reduce stomach acid and promote ulcer healing. The company leverages its extensive research and development capabilities to continuously innovate and improve treatment options for gastric ulcers and other gastrointestinal conditions.
Takeda Pharmaceutical Company Limited
A global, research and development-driven biopharmaceutical company headquartered in Japan, Takeda focuses on developing innovative medicines in areas such as oncology, gastroenterology, neuroscience, and rare diseases. In the realm of gastric ulcer treatment, it offers effective therapies like proton pump inhibitors (e.g., Lansoprazole) that help reduce stomach acid and promote healing. The company is committed to improving patient outcomes through advanced research and a strong pipeline of therapeutic solutions.
Other key players in the market include Boehringer Ingelheim International GmbH, Nuvo Pharmaceuticals Inc. (Aralez Pharmaceuticals), Daiichi Sankyo Company, Limited, Novartis AG, and Pfizer Inc., among others.
Key Questions Answered in the Gastric Ulcer Treatment Market Report
- What was the 8 MM gastric ulcer treatment market value in 2024?
- What is the 8MM gastric ulcer treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on the drug class?
- What is market segmentation based on the distribution channel?
- What is market segmentation based on the route of administration?
- What are the major factors aiding the gastric ulcer treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major market trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the rise in the geriatric population impact the market size?
- How do the technological innovations in gastric ulcer treatment affect the market landscape?
- Which application area is expected to have a high market value in the coming years?
- Who are the key players involved in the gastric ulcer treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Gastric Ulcer Treatment Market Overview – 8 Major Markets
- 3.1 Gastric Ulcer Treatment Market Historical Value (2018-2024)
- 3.2 Gastric Ulcer Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Gastric Ulcer Treatment Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Gastric Ulcer Treatment Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality, by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment seeking rate, by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Gastric Ulcer Treatment Market Landscape – 8 Major Markets
- 8.1 Gastric Ulcer Treatment: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Gastric Ulcer Treatment: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Route of Administration
- 9 Gastric Ulcer Treatment Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Gastric Ulcer Treatment Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Gastric Ulcer Treatment Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Gastric Ulcer Treatment Market (2018-2034) by Drug Class
- 12.1.1 Market Overview
- 12.1.2 Antacids
- 12.1.3 Anti-Histamines
- 12.1.4 Antibiotics
- 12.1.5 H2 Receptor Antagonist
- 12.1.6 Proton Pump Inhibitor (PPIs)
- 12.2 Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
- 12.2.1 Market Overview
- 12.2.2 Retail Pharmacy
- 12.2.3 Hospital Pharmacy
- 12.2.4 Online Pharmacy
- 12.3 Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.4 Gastric Ulcer Treatment Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Gastric Ulcer Treatment Market (218-2034)
- 13.1 United States Gastric Ulcer Treatment Market Historical Value (2018-2024)
- 13.2 United States Gastric Ulcer Treatment Market Forecast Value (2025-2034)
- 13.3 United States Gastric Ulcer Treatment Market (2018-2034) by Drug Class
- 13.3.1 Market Overview
- 13.3.2 Antacids
- 13.3.3 Anti-histamines
- 13.3.4 Antibiotics
- 13.3.5 H2 Receptor Antagonist
- 13.3.6 Proton Pump Inhibitor (PPIs)
- 13.4 United States Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
- 13.4.1 Market Overview
- 13.4.2 Retail Pharmacy
- 13.4.3 Hospital Pharmacy
- 13.4.4 Online Pharmacy
- 13.5 United States Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 14 EU-4 and United Kingdom Gastric Ulcer Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Gastric Ulcer Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Gastric Ulcer Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Gastric Ulcer Treatment Market (2018-2034) by Drug Class
- 14.3.1 Market Overview
- 14.3.2 Antacids
- 14.3.3 Anti-Histamines
- 14.3.4 Antibiotics
- 14.3.5 H2 Receptor Antagonist
- 14.3.6 Proton Pump Inhibitor (PPIs)
- 14.4 EU-4 and United Kingdom Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
- 14.4.1 Market Overview
- 14.4.2 Retail Pharmacy
- 14.4.3 Hospital Pharmacy
- 14.5 EU-4 and United Kingdom Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 15 Japan Gastric Ulcer Treatment Market
- 15.1 Japan Gastric Ulcer Treatment Market Historical Value (2018-2024)
- 15.2 Japan Gastric Ulcer Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Gastric Ulcer Treatment Market (2018-2034) by Drug Class
- 15.3.1 Market Overview
- 15.3.2 Antacids
- 15.3.3 Anti-Histamines
- 15.3.4 Antibiotics
- 15.3.5 H2 Receptor Antagonist
- 15.3.6 Proton Pump Inhibitor (PPIs)
- 15.4 Japan Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
- 15.4.1 Market Overview
- 15.4.2 Retail Pharmacy
- 15.4.3 Hospital Pharmacy
- 15.4.4 Online Pharmacy
- 15.5 Japan Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 16 India Gastric Ulcer Treatment Market
- 16.1 India Gastric Ulcer Treatment Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Gastric Ulcer Treatment Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Gastric Ulcer Treatment Market (2018-2034) by Drug Class
- 16.3.1 Market Overview
- 16.3.2 Antacids
- 16.3.3 Anti-Histamines
- 16.3.4 Antibiotics
- 16.3.5 H2 Receptor Antagonist
- 16.3.6 Proton Pump Inhibitor (PPIs)
- 16.4 India Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
- 16.4.1 Market Overview
- 16.4.2 Retail Pharmacy
- 16.4.3 Hospital Pharmacy
- 16.4.4 Online Pharmacy
- 16.5 India Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 Japan PMDA
- 17.1.4 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Strategic Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Market Share by Top 5 Companies
- 21.2 AstraZeneca PLC
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Takeda Pharmaceutical Company Limited
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 Boehringer Ingelheim International GmbH
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Nuvo Pharmaceuticals Inc. (Aralez Pharmaceuticals)
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Daiichi Sankyo Company, Limited
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 Novartis AG
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Pfizer, Inc
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 22 Gastric Ulcer Treatment Treatment Drugs - Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
